RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

被引：0

作者：

Alvarez, A. ^{[1
]}

Valduvieco, I. ^{[2
]}

Arance, A. ^{[3
]}

Delgado, R. ^{[4
]}

Berciano, M. A. ^{[5
]}

Lopez Campos, F. ^{[6
]}

Soria, A. ^{[7
]}

Romero, J. L. ^{[8
]}

Sanchez Maurino, P. ^{[9
]}

Lucas, A. ^{[10
]}

Martin Liberal, J. ^{[10
]}

Prada, P. J. ^{[11
]}

Garcia Castano, A. ^{[12
]}

Alamo, M. C. ^{[13
]}

Puertas, E. ^{[14
]}

Gonzalez Cao, M. ^{[15
]}

Conde, A. ^{[16
]}

Diaz Beveridge, R. ^{[17
]}

Corona, J. A. ^{[18
,19
]}

Aguado, C. ^{[20
]}

Foro, P. ^{[21
]}

Vidal, J. ^{[22
]}

Lopez Soler, F. ^{[23
]}

Cerezuela Fuentes, P. ^{[24
]}

Marquez Rodas, I. ^{[25
]}

机构：

[1] HGU Gregorio Maranon, Madrid, Spain

[2] H Clin, Radiat Oncol, Barcelona, Spain

[3] H Clin, Med Oncol, Barcelona, Spain

[4] H Reg Malaga, Radiat Oncol, Malaga, Spain

[5] HU Reg & Virgen de la Victoria, Med Oncol, Unidad Gest Intercentros, Malaga, Spain

[6] H Ramon y Cajal, Radiat Oncol, Madrid, Spain

[7] H Ramon y Cajal, Med Oncol, Madrid, Spain

[8] HU Reina Sofia, Radiat Oncol, Cordoba, Spain

[9] HU Reina Sofia, Med Oncol, Cordoba, Spain

[10] ICO LHospitalet, Radiat Oncol, Barcelona, Spain

[11] ICO LHospitalet, Med Oncol, Barcelona, Spain

[12] H Valdecilla, Radiat Oncol, Santander, Spain

[13] H Valdecilla, Med Oncol, Santander, Spain

[14] HU Virgen Macarena, Med Oncol, Seville, Spain

[15] HU Dexeus, Radiat Oncol, Barcelona, Spain

[16] HU Dexeus, Med Oncol, Barcelona, Spain

[17] H la Fe, Radiat Oncol, Valencia, Spain

[18] H la Fe, Med Oncol, Valencia, Spain

[19] H Clin San Carlos, Radiat Oncol, Madrid, Spain

[20] H Clin San Carlos, Med Oncol, Madrid, Spain

[21] H del Mar, Radiat Oncol, Barcelona, Spain

[22] H del Mar, Med Oncol, Barcelona, Spain

[23] HCU Virgen de la Arrixaca, IMIB, Radiat Oncol, Murcia, Spain

[24] HCU Virgen de la Arrixaca, IMIB, Med Oncol, Murcia, Spain

[25] HGU Gregorio Maranon, Madrid, Spain

来源：

RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO-1557

引用

页码：S1264 / S1264

页数：1

共 30 条

[21] Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases.
Peereboom, David M.
Chao, Samuel T.
Suh, John H.
Wang, Ding
Mikkelsen, Tom
Brewer, Cathy J.
Smolenski, Kathy N.
Parsons, Michael W.
Elson, Paul
Angelov, Lilyana
Barnett, Gene H.
Vogelbaum, Michael A.
Weil, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
Kotani, Daisuke
Bando, Hideaki
Taniguchi, Hiroya
Masuishi, Toshiki
Komatsu, Yoshito
Yamaguchi, Kensei
Nakajima, Takako
Satoh, Taroh
Nishina, Tomohiro
Esaki, Taito
Nomura, Shogo
Takahashi, Koji
Iida, Shinobu
Matsuda, Seiko
Motonaga, Shinya
Fuse, Nozomu
Sato, Akihiro
Fujii, Satoshi
Ohtsu, Atsushi
Ebi, Hiromichi
Yoshino, Takayuki
ESMO OPEN, 2020, 5 (01)
[23] A phase II, open-label, randomized, multicenter trial of encorafenib plus binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)
Davies, M. A.
Weber, J. S.
Flaherty, K. T.
McArthur, G. A.
Reddy, M. B.
Golden, A.
Culbertson, J. L.
Thomas, C. T.
Tawbi, H. A.
Long, G. V.
ANNALS OF ONCOLOGY, 2019, 30 : 562 - 563
[24] Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial
Davies, Michael A.
Martins, Karla D.
Sessa, Tracey
Swann, Suzanne
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] First-line-Therapie beim inoperablen oder metastasierten MelanomRandomisierte, offene, multizentrische Phase-I/II-Studie zur Sicherheit und Wirksamkeit einer Triple-Therapie mit dem BRAF-Inhibitor Encorafenib und dem MEK-Inhibitor Binimetinib in Kombination mit dem Anti-PD-1-Antikörper Pembrolizumab bei Patienten mit BRAF-mutiertem MelanomFirst-line therapy for inoperable or metastatic melanomaRandomized, open, multicenter phase I/II study on the safety and efficacy of triple therapy with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in combination with the anti-PD-1 antibody pembrolizumab in patients with BRAF-mutated melanoma
L. Zimmer
E. Livingstone
D. Schadendorf
Forum, 2020, 35 (2) : 146 - 147
[26] COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM).
Davies, Michael A.
Robert, Caroline
Long, Georgina V.
Grob, Jean Jacques
Flaherty, Keith T.
Arance, Ana
Chiarion-Sileni, Vanna
Thomas, Luc
Lesimple, Thierry
Mortier, Laurent
Moschos, Stergios J.
Hogg, David
Rodas, Ivan Marquez
Del Vecchio, Michele
Lebbe, Celeste
Meyer, Nicolas
Zhang, Ying
Huang, Yingjie
Mookerjee, Bijoyesh
Saiag, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Case Report: Rapid Regression of disseminated Brain Filiae of malignant Melanoma after single PD1 Antibody Pembrolizumab plus six Weeks of targeted Therapy with Encorafenib and Binimetinib after prior Relapse/Progress with Vemurafenib and Cobimetinib under seven Months Treatment for BRAF V600E Mutation
Bender, A.
Geschnell, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 33 - 34
[28] SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.
Ascierto, Paolo Antonio
Dummer, Reinhard
Melero, Ignacio
Palmieri, Giuseppe
Giannarelli, Diana
Abrami, Elena
Curvietto, Marcello
Simeone, Ester
Grimaldi, Antonio Maria
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma
Dummer, R.
Sandhu, S.
Hassel, J. C.
Munoz, E.
Berking, C.
Gesierich, A.
Ascierto, P. A.
Esposito, O.
Carter, K.
Antona, V.
Radhakrishnan, R.
Cui, X.
Caponigro, G.
Jaeger, S.
Demuth, T.
Miller, W. H., Jr.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S667 - S668
[30] BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).
Kirkwood, John M.
Long, Georgina V.
Trefzer, Uwe
Davies, Michael A.
Ascierto, Paolo Antonio
Chapman, Paul B.
Puzanov, Igor
Hauschild, Axel
Robert, Caroline
Kefford, Richard
Goodman, Vicki L.
Switzky, Julie C.
Swann, R. Suzanne
Martin, Anne-Marie
Guckert, Mary E.
Streit, Michael R. W.
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 →